“Migraine is a common and complex brain disorder that affects 10 million people in the UK, impacting their ability to work, relationships and mental health. It’s poorly understood by the public and even many health professionals, and there are challenges around diagnosis, care and access to the right treatment. ” – Rob Music, CEO, The Migraine Trust
Rob Music, CEO, The Migraine Trust, joins touchNEUROLOGY to discuss and report on a recent parliamentary event held about improving migraine care: ensuring patient-focussed diagnosis and treatment in the UK. He discusses migraine diagnosis issues, preventative therapies, access to care, and future recommendations from The Migraine Trust.
- Report: State of the Migraine Nation, Dismissed for too long: Recommendations to improve migraine care in the UK
- What are the major challenges in diagnosing migraine and how long do people typically wait to obtain a diagnosis? (0:09)
- What feedback have you had from patients in terms of access to specialist care and newer drugs, particularly preventative therapies? (1:30)
- Why do you think these problems in migraine healthcare have occurred? (2:55)
- What are the recommendations of The Migraine Trust on how these problems can be addressed? (4:23)
Disclosures: Rob Music has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Share this Video
Related Videos In Headache Disorders
Robert Music, The Migraine Trust: Improving migraine care – ensuring patient-focussed diagnosis and treatment in the UK
“Migraine is a common and complex brain disorder that affects 10 million people in the UK, impacting their ability to work, relationships and mental health. It’s poorly understood by the public and even many health professionals, and there are challenges around diagnosis, care and access to the right treatment. ” – Rob Music, CEO, The […]
Raquel Gil-Gouveia, EAN 2022: Highlights in headache and migraine – Treatment advances, strategies for prevention, Anti-CGRP use in migraine, COVID-19
Headache is one of the most common nervous system disorders. In an interview with touchNEUROLOGY, Dr Raquel Gil-Gouveia (Hospital da Luz, Lisbon, Portugal) summarizes the ePoster session she chaired at EAN 2022, ranging from topics such as how COVID-19 has impacted on young people with headaches, the potential of new treatments such as eptinezumab and […]
Stewart Tepper, AAN 2022: Limitations of current treatments for acute migraine
The limitations of the current treatment of acute migraine are said to be patient variability and migraine attack variability. Prof. Stewart Tepper (Dartmouth-Hitchcock Medical Centre, Lebanon, NH, USA) discusses the limitations of current treatments for acute migraine and how new treatments overcome these. The abstract entitled ‘Efficacy and Safety of AXS-07 (MoSEIC Meloxicam-Rizatriptan) for the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!